Why This Company is Set for a Major Breakout
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors.
An incredibly unique stem cell firm we like is, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the street. As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar currently, but that could all change in the blink of an eye. BRTX presents an incredible opportunity to investors that will have discovered the company before BRTX starts its phase 2 clinical trial using BRTX-100. The company recently announced that the Journal of Translational Medicine has published the results of the company's study evaluating the benefits of long-term hypoxic culturing of human bone marrow-derived mesenchymal stem cells, which are used in the company's BRTX-100 product. If this is your first time hearing about BRTX, start doing your own research right away.
These here are a few biotech companies to put on your radar: BioRestorative Therapies, Inc. (BRTX), Aphria, Inc. (APHQF), The Green Organic Dutchman Holdings, Ltd. (TGODF), Verastem, Inc. (VSTM) and Arrowhead Pharmaceuticals, Inc. (ARWR).
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $11.85M Share Price: $1.47
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Company has entered into a one-year material transfer agreement with the University of Pennsylvania providing the University access to the Company's proprietary brown adipose tissue fat cells.
Aphria, Inc. (APHQF)
Market Cap: $3.26B Share Price: $14.13
Aphria Inc. (APHQF) announced closing the acquisition of LATAM Holdings Inc. from Scythian Biosciences (SCCYF). The Transaction was funded by the assumption of US$1 million of existing LATAM Holdings debt with the remaining consideration funded by the issuance of 15,678,310 common shares of Aphria. The closing was pursuant to the terms of the definitive share purchase agreement previously announced by the Company on July 17, 2018 .
The Green Organic Dutchman Holdings, Ltd. (TGODF)
Market Cap: $1.11B Share Price: $4.41
On August 21st, the company announced it signed an agreement to acquire 100% of the issued and outstanding shares of privately-held HemPoland for $7.75M cash and 1,968,323 restricted TGODF shares currently worth $7.75M, which will be escrowed for a term of three years from closing.
Verastem, Inc. (VSTM)
Market Cap: $226.24M Share Price: $4.66
Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, will present at the following upcoming investor conferences:
The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00pm EDT in New York City, NY, USA
The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 8:00am EDT in New York City, NY, USA
Arrowhead Pharmaceuticals, Inc. (ARWR)
Market Cap: $1.13B Share Price: $12.93
Arrowhead Pharmaceuticals Inc (ARWR) recently announced Johnson & Johnson (JNJ) would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty-one thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC,For Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC
